Drug Database
FA

Factor VIII (ReFacto AF / Xyntha)

✓ Approved

Sobi · F8 · Recombinant Proteins

What is Factor VIII?

Factor VIII is a recombinant proteins developed by Sobi. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesReFacto AF, Xyntha
CompanySobi
Drug ClassRecombinant Proteins, Cell-based Therapies
Molecular TargetF8
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Sobi

Mechanism of Action

Molecular Targets

Factor VIII acts on 1 molecular target:

F8coagulation factor VIII (AHF, FVIII)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

Factor VIII is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersFactor VIII deficiency✓ Approved

Related Research Articles

PubMedFrontiers in public health2026-09-20

Factors and a configurational pathway associated with lower turnover intention among high-level medical professionals in county-level hospitals in China: a multicenter cross-sectional study.

Dong Shuxin S, Tai Qiuyuan Q, Yao Yiming Y, Shen Junlong J et al.

This study developed a context-specific framework of perceived conditions related to lower turnover intention among high-level medical professionals in county-level hospitals and examined the configurational pattern associated with a high retention-oriented score. A multicenter cross-sectional study combined three Delphi rounds, psychometric evaluation, and fuzzy-set qualitative comparative analysis (fsQCA). The Delphi process progressed from 33 items in round 1-37 in round 2 and 34 assessed in round 3, with 33 retained for the survey. From July 2024 to February 2025, online and paper questionnaires were distributed in 10 county-level public hospitals in Jiangsu Province. Of 635 questionnaires distributed, 611 were returned and 579 were valid. The sample was randomly split for exploratory factor analysis (EFA; n = 289) and confirmatory factor analysis (CFA; n = 290). fsQCA used the full sample, a frequency threshold of 10, consistency of 0.85, and proportional reduction in inconsistency (PRI) of 0.70. Thirty experts participated in Delphi round 1 and 29 in rounds 2 and 3 after one expert retired. The final 31 condition items showed high internal consistency (alpha = 0.971), suggesting both reliability and possible redundancy. Parallel analysis in the EFA half-sample suggested two factors, whereas a theory-constrained five-factor solution remained interpretable. In the CFA half-sample, the correlated five-factor model fit was marginal (Satorra-Bentler chi-square = 1350.48, df = 424, CFI = 0.903, TLI = 0.893, RMSEA = 0.087, 90% CI 0.082-0.092, SRMR = 0.042) and was similar to the second-order and bifactor models. No condition met the 0.90 necessity threshold. The corrected truth-table analysis identified one high-score configuration, PD*IES*CIS*OIE (consistency = 0.953; PRI = 0.917; coverage = 0.631). PD and CIS were core present conditions; IES and OIE were peripheral present conditions; IEPS was not included. A single sufficient configuration combined favorable perceptions of personal development, institutional/environmental support, compensation/incentive support, and organizational/interpersonal empowerment. The result does not support multiple substitutable pathways. Because the outcome was a retention-oriented score derived from a turnover-intention measure, the findings concern lower turnover intention rather than directly observed retention. The cross-sectional, individual-level results indicate associations and should not be interpreted causally or at the hospital level.

PMID 42763469
Read full article →
PubMedCureus2026-09-20

GLT6D1 rs1537415 G Allele and Advanced Periodontitis: A Meta-Analysis.

Karaoulas Theofanis A TA, Xirouchakis Christoforos C, Neophytou Chariklia C, Fragkioudakis Ioannis I

This meta-analysis aimed to evaluate the association of the GLT6D1 rs1537415 G allele with susceptibility to periodontitis stage III/IV, grade B or C. Adhering to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, three eligible studies were identified through comprehensive searches of PubMed, Web of Science, and Scopus. Data from 2,185 participants (668 cases and 1,517 controls) were analyzed using random-effects models to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Heterogeneity was assessed using Chi² and I² statistics. Formal testing for publication bias was precluded by the small number of studies (n = 3). The meta-analysis demonstrated a significant association between the rs1537415 G allele and severe periodontitis, with a pooled OR of 1.58 (95% CI: 1.28-1.95). Subgroup analyses showed consistent associations in European and Sudanese populations, whereas no significant association was observed in the Brazilian cohort. Sensitivity analysis excluding the largest Genome-Wide Association Study (GWAS) attenuated the association to a non-significant level (OR = 1.37; 95% CI: 0.87 to 2.16), indicating that a single study largely drove the overall effect; the pooled estimate should therefore be interpreted with caution. The GLT6D1 rs1537415 G allele may represent a genetic risk factor for severe periodontal diseases, particularly stage III/IV and grade B/C, suggesting a possible role in immune modulation. Further research involving larger, multi-ethnic cohorts is crucial to validate these associations and explore gene-environment interactions.

PMID 42763709
Read full article →
PubMedUltrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology2026-09-20

Imaging in gynecological disease (32): clinical and ultrasound characteristics of early abdominal ectopic pregnancy.

Berg L L, De Braud L V LV, Bean E E, Lomheim M M et al.

To compare clinical and sonographic characteristics of first-trimester abdominal ectopic pregnancy (AEP) with those of tubal ectopic pregnancy (TEP), and to define ultrasound-based diagnostic criteria for AEP. This was a retrospective case-control study comparing cases of AEP diagnosed at four centers with controls diagnosed with TEP, between May 2008 and May 2025. AEP was defined as a pregnancy implanted within the peritoneal cavity outside the uterus, ovaries and Fallopian tubes. We compared demographics, clinical and ultrasound findings and clinical outcomes between the groups. We identified the key ultrasound features of first-trimester AEP and used these to develop refined diagnostic criteria. During the study period, 19 cases of AEP were identified and compared to 57 controls with TEP. The groups were matched for age, parity and gestational age at presentation. Compared with TEP, AEP was more likely to occur in pregnancies conceived via in-vitro fertilization (6/19 (32%) vs 5/57 (9%); odds ratio (OR) 4.80 (95% CI, 1.27-18.21); P = 0.02; adjusted OR (aOR), 5.02 (95% CI, 1.24-20.25); P = 0.02) and patients with AEP were less likely to present with vaginal bleeding (5/18 (28%) vs 40/57 (70%); OR, 0.16 (95% CI, 0.05-0.53); P = 0.003; aOR, 0.17 (95% CI, 0.05-0.64); P = 0.009). With respect to clinical outcomes, patients with AEP were more likely to have significant blood loss (≥ 500 ml) at surgery (4/16 (25%) vs 1/36 (3%); OR, 11.67 (95% CI, 1.18-114.90); P = 0.04) and require blood transfusion (4/19 (21%) vs 0/56 (0%); P = 0.003). Four diagnostic ultrasound criteria for AEP were identified: (1) the presence of a gestational sac or trophoblast separate from the uterus and ovaries; (2) the absence of a hypoechogenic tissue layer surrounding the pregnancy; (3) a negative 'sliding organs' sign; and (4) trophoblastic blood flow arising from the peritoneum detected on color Doppler examination. Assisted conception is a risk factor for a pregnancy implanting into the peritoneal cavity. Early ultrasound diagnosis of AEP is important to reduce the risk of major intra-abdominal bleeding, which is significantly higher in AEP compared with TEP. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

PMID 42763435
Read full article →
PubMedASN neuro2026-09-20

Hyperoxia Inhibits the Growth of Mouse Forebrain Oligodendrocyte Progenitors but Promotes Their Differentiation.

Moore Lisamarie L, McLane Lauren L, Wahl Stacey S, Ornelas Isis M IM et al.

Oligodendrocytes facilitate saltatory conduction and they support both neuronal and axonal survival; thus, when they are diseased or damaged, neurological problems ensue. Oligodendrocyte progenitors (OPCs) have been successfully isolated from rodents using magnetic beads, immunopanning and differential adhesion. Whereas rat OPCs are easy to propagate in vitro, expanding mouse OPCs in vitro has not been straightforward, which is problematic given that mice have been used to generate the majority of genetically engineered disease models. In this study, we developed and characterized a reproducible, straightforward method to prepare large numbers of nearly homogeneous cultures of mouse OPCs. Using the McCarthy and de Vellis mechanical separation method, we isolated OPCs from a mixture of glial cells and plated them onto fibronectin-coated tissue culture plates in a biochemically defined medium supplemented with fibroblast growth factor-2 (FGF-2) and medium conditioned by B104 neuroblastoma cells. However, when maintained in a standard tissue culture incubator, they proliferated very slowly and ∼ 20% died. By contrast, when they were maintained in an incubator with 2% oxygen they proliferated more rapidly and could be expanded for multiple passages with high viability. After three passages, greater than 99% of these OPCs expressed markers of early OPCs. In medium containing only FGF-2 they progressed to late-stage OPCs. When a medium supplemented with T3 was provided, a large subset of OPCs differentiated into O4+/MBP+ oligodendrocytes with sheet-like membranes. However, between 3 and 6 passages, less than 20% of the OPCs differentiated into MBP+ oligodendrocytes and this was associated with a loss of Sox-10. These studies reveal significant differences between mouse and rat OPCs and a role for oxygen tension in mouse OPC proliferation and differentiation.

PMID 42763430
Read full article →
PubMedIranian journal of pharmaceutical research : IJPR2026-09-20

Protective Effect of Methoxsalen on Spinal Cord Injury in the Rat Model via Regulation of the PI3K/Akt Pathway.

Zhaohu Mao M, Zheng Zhang Z, Qunqun Shan S

Spinal cord injury (SCI) is a major cause of disability, and the management of secondary injury remains challenging. This study evaluated the protective effects of methoxsalen against SCI and investigated its potential mechanism of action. Network pharmacology and molecular docking were performed to identify the molecular targets of methoxsalen for the treatment of SCI. SCI was induced in rats by laminectomy, and methoxsalen (12 and 24 mg/kg, p.o.) was administered for 14 days after SCI induction. Motor function was assessed using the Basso, Beattie, and Bresnahan (BBB) score, and spinal cord inflammation was evaluated by assessing water deposition and inflammatory cytokine levels in SCI rats. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to assess the mRNA expression of phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT) in SCI rats. Molecular docking data showed that methoxsalen interacted with AKT, PI3K, and nuclear factor-κB (NF-κB), with binding energies of -9.1, -9.2, and -9.4 kcal/mol, respectively. The BBB score was significantly improved in the methoxsalen-treated group compared with the SCI group. MDA (18.6 ± 0.9 nmol/mg) and ROS (1.30 ± 0.04-fold) levels were significantly reduced, whereas GSH (92.0 ± 2.2 µM/mg) and SOD (54.2 ± 1.3 U/mg) levels were increased in the methoxsalen-treated group compared with the SCI group. Methoxsalen treatment ameliorated inflammatory alterations and cytokine levels in rats with SCI. The mRNA expression of PI3K, AKT, and NF-κB was attenuated in spinal cord tissue from methoxsalen-treated rats with SCI. Methoxsalen treatment improved motor function in rats with SCI by modulating the PI3K/AKT signaling pathway.

PMID 42763726
Read full article →
PubMedJournal of research in nursing : JRN2026-09-20

Psychometric properties of the Persian version of Pressure Ulcer Management Self-Efficacy Scale for nurses.

Mohammadzade Sarhadi Sajjad S, Najafi Fereshteh F, Fendereski Afsaneh A, Sharifi Simin S

Pressure ulcers remain a major clinical challenge, and nurses' self-efficacy is essential for their prevention and management. The Pressure Ulcer Management Self-Efficacy Scale (PUM-SES) for nurses was developed to assess this competency. This study aimed to translate, culturally adapt and validate the Persian version of the PUM-SES (PUM-SES-P) among Iranian nurses. This three-phase study began with forward and back translation. In phase two, face and content validity were evaluated by 10 nurses and 15 experts, respectively, and construct validity and reliability were assessed among 200 and 30 nurses. In phase three, criterion-related and convergent validity were evaluated among 100 nurses. Content validity indices were favourable (content validity index = 0.97, content validity ratio = 0.90), and factor analysis supported a four-factor structure. The scale showed high internal consistency (α = 0.91) and acceptable test-retest reliability (r = 0.89). Correlations with General Self-Efficacy Scale (r = 0.88) and Attitude towards Pressure Ulcer Prevention instrument (r = 0.77, p < 0.001) supported validity. The PUM-SES-P appears to be a valid, reliable instrument for assessing pressure ulcer self-efficacy among Iranian nurses in this sample, offering a potentially useful resource for nurse educators and unit managers. Further validation in larger, more diverse samples is recommended before broader clinical application.

PMID 42763473
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Factor VIII